EGFR and neoplasm: First line targeted monotherapies (e.g. EGFR antagonists, ALK inhibitor, etc.)and immunotherapies (PD1/PDL1 inhibitors) have been well-established in tumours expressing targetable mutations, and has become the standard of care.79